
Nicola K Love,1,2 Alex J Elliot,1,2,3 Rachel M Chalmers,4 Amy Douglas,1 Saheer Gharbia,1 Jacquelyn McCormick,1 Helen Hughes,1,2 Roger Morbey,1,3 Isabel Oliver,1,5 Roberto Vivancos,1,2 Gillian Smith1,2,3

ABSTRACT

Objective To establish the impact of the first 6 months of the COVID-19 outbreak response on gastrointestinal (GI) infection trends in England.

Design Retrospective ecological study using routinely collected national and regional surveillance data from seven UK Health Security Agency coordinated laboratory, outbreak and syndromic surveillance systems, using key dates of UK governmental policy change to assign phases for comparison between 2020 and historic data.

Results Decreases in GI illness activity were observed across all surveillance indicators as COVID-19 cases began to peak. Compared with the 5-year average (2015–2019), during the first 6 months of the COVID-19 response, there was a 52% decrease in GI outbreaks reported (1544 vs 3208 (95% CI 2938 to 3478)) and a 34% decrease in laboratory confirmed cases (27 859 vs 42 495 (95% CI 40 068 to 44 922)). GI indicators began to rise during the first lockdown and lockdown easing, although all remained substantially lower than historic figures. Reductions in laboratory confirmed cases were observed across all age groups and both sexes, with geographical heterogeneity observed in diagnosis trends. Health seeking behaviour changed substantially, with attendances decreasing prior to lockdown across all indicators.

Conclusions There has been a marked change in trends of GI infections in the context of the COVID-19 pandemic. The drivers of this change are likely to be multifactorial; while changes in health seeking behaviour, pressure on diagnostic services and surveillance system ascertainment have undoubtably played a role, there has likely been a true decrease in the incidence for some pathogens resulting from the control measures and restrictions implemented. This suggests that if some of these changes in behaviour such as improved hand hygiene were maintained, then we could potentially see sustained reductions in the burden of GI illness.

INTRODUCTION

The COVID-19 pandemic has resulted in unparalleled challenges for society.1 During 2020, the UK Government implemented a stepwise series of public health measures designed initially to contain, and then delay transmission of the virus (figure 1). These measures ranged from public health information campaigns, rapid identification of cases and their contacts and isolation of those contacts in the initial phase of the outbreak (February to mid-March 2020), with additional measures such as social distancing, education and business closures and enforceable ‘lockdown’ measures in the delay phase (mid-March onwards).2 Changes to healthcare provision and patient management were implemented concurrently to alleviate pressure on the National Health Service (NHS) and minimise nosocomial transmission of COVID-19 while continuing to provide essential care.2

There is a growing body of evidence indicating that the COVID-19 pandemic and implemented control measures have had indirect impacts on other health conditions. Substantial decreases have been observed in emergency department (ED) attendances,
with decreasing presentation of conditions such as strokes, surgical emergencies and cardiac emergencies, delays to cancer diagnoses, and concerns raised about delayed presentation and associated negative outcomes. 3–7 Less well documented are any indirect effects on communicable diseases, which are often controlled using similar non-pharmaceutical interventions to those implemented in the COVID-19 response. 8

Gastrointestinal (GI) infections are an important infectious cause of morbidity and mortality globally, placing a considerable burden on primary and secondary healthcare services. In England, it is estimated that there are in excess of 17 million cases annually, resulting in over 1 million healthcare consultations and around 90,000 confirmed laboratory diagnoses. 9, 10 Transmission of GI pathogens is typically faecal–oral, predominantly through consumption of contaminated food or water, or contact with infected individuals, animals or the contaminated environment and fomites; importance of transmission route varies substantially by pathogen. Control measures

Figure 1 Gastrointestinal (GI) outbreaks and GI pathogens* reported to the UK Health Security Agency between week 1 and week 31 2020 and the 5-year weekly average (95% CI), indicating key public health measures introduced during the COVID-19 response. *Organisms: Campylobacter spp, STEC O157, STEC non-O157, Listeria spp, non-typhoidal Salmonella spp, typhoidal Salmonella, Shigella spp, norovirus, Cryptosporidium spp and Giardia sp. SGSS, Second Generation Surveillance System.
implemented during the COVID-19 response including improved hand hygiene, reduced social contact, increased environmental cleaning and closure of premises, are all known to be effective in reducing GI infections, primarily those spread by person-to-person transmission and environmental contamination.8

Using routinely collected surveillance data from several English surveillance systems coordinated by the UK Health Security Agency (UKHSA; please note - on 1st October 2021, the UK Health Security Agency and Office for Health Improvement and Disparities replaced Public Health England), this study aimed to establish what impact the first 6 months of the COVID-19 pandemic had on trends in GI infections.

### METHODS

#### Surveillance systems

A retrospective ecological study was conducted by performing secondary analyses on routinely collected national and regional surveillance data from seven national UKHSA coordinated surveillance systems, detailed in Table 1, and Google Trend data. Systems included outbreak monitoring (HPZone), laboratory notifications (Second Generation Surveillance System (SGSS) and EpiNorth3), and real-time syndromic surveillance.

Table 1 UKHSA surveillance systems and indicators for gastrointestinal infection surveillance

<table>
<thead>
<tr>
<th>System</th>
<th>Coverage</th>
<th>Reporting statistic</th>
<th>Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPZone</td>
<td>National (by UKHSA regional centre)</td>
<td>Statutory notifications of suspected or confirmed outbreaks of food poisoning, haemolytic uaeemic syndrome (HUS) and infectious bloody diarrhoea. Outbreaks of gastroenteritis in closed settings.</td>
<td>Food poisoning; HUS; Infectious bloody diarrhoea. GI illness in closed settings (care homes, schools, prisons).</td>
</tr>
<tr>
<td>EpiNorth3</td>
<td>North East England residents (approx. 2.6 million population)</td>
<td>Notifiable infections reported in North East England linked with enhanced exposure information from routine surveillance questionnaires conducted by environmental health officers for selected organisms.</td>
<td>Specified GI pathogens: Cryptosporidium, Shiga toxin producing E. coli (STEC), Giardia, Salmonella, Shigella.</td>
</tr>
<tr>
<td>SGSS (Second Generation Surveillance System)</td>
<td>All NHS laboratories in England</td>
<td>Routine laboratory notifications from NHS laboratories including statutory notifications of laboratory confirmed notifiable organisms.</td>
<td>Specified GI pathogens: Campylobacter, Cryptosporidium, E. coli (STEC), Giardia, Listeria, norovirus, non-typhoidal Salmonella, Shigella.</td>
</tr>
<tr>
<td>GP in hours</td>
<td>Approximately 4000 GP practices in England</td>
<td>In-hours (weekdays, daytime) GP consultation rates per 100 000 registered patients.</td>
<td>Gastroenteritis—clinical diagnoses, diarrhoea and vomiting.</td>
</tr>
<tr>
<td>GP out of hours</td>
<td>Approximately 60% coverage of GP out-of-hours activity in England</td>
<td>Out-of-hours and unscheduled care consultations for indicator as a percentage of total read-coded consultations.</td>
<td>Gastroenteritis—clinical diagnoses, diarrhoea and vomiting.</td>
</tr>
<tr>
<td>Emergency department (ED)</td>
<td>Sentinel system. 80 EDs across England</td>
<td>Percentage of emergency department visits with a recorded diagnosis code.</td>
<td>Gastroenteritis—clinical diagnoses.</td>
</tr>
</tbody>
</table>

GI, gastrointestinal; GP, general practitioner; NHS, National Health Service; UKHSA, UK Health Security Agency.

Time periods

Extracted data covering weeks 1–31 2020 (30 December 2019–2 August 2020), and historic comparator data from week 1 to week 31 2015–2019, was split into seven COVID-19 pandemic ‘phases’ for comparison, determined by the key dates of UK governmental policy changes implemented during the COVID-19 response (figure 1). These phases comprised: pre-outbreak (phase 1); early outbreak (phase 2); pre-lockdown (phase 3); early lockdown (phase 4); late lockdown (phase 5); lockdown easing (phase 6) and further easing (phase 7; figure 1).

Data analysis

Total weekly GI outbreaks recorded in HPZone were determined for the seven phases of 2020 and the 5-year average (2015–2019) with 95% CIs calculated. HPZone data were further analysed by outbreak setting, UKHSA region and pathogen (including if the suspected pathogen was laboratory confirmed). Pseudonymised SGSS data for
selected laboratory confirmed organisms (Campylobacter spp, Cryptosporidium spp, Shiga-toxin producing E. coli (STEC), Giardia spp, Listeria spp, norovirus, non-typhoidal Salmonella spp, Shigella spp) were grouped by week of specimen sample date. Age group specific rates were calculated per 100 000 population using Office National specimen sample date. Age group specific rates were calculated per 100 000 population using Office National Statistics 2019 England mid-year population estimates. Cumulative regional and local authority rates per 100 000 population were determined for week 1–31 2020 and the 5-year average for GI infections reported to SGSS for nine UKHSA regions (ranging from 2.6 to 9.1 million population) and 150 local authority areas (average population size: 375 686). For geographies, risk ratios and percentage relative effects were calculated, and Pearson’s correlation was performed for each local authority area using the cumulative COVID-19 rate per 100 000 population.13

Syndromic data were analysed as described elsewhere for data between week 1 and week 31 2020, with the same period in 2019 used as a comparator. Google Trend searches were performed for key phrases associated with GI illness in England, as described previously. A score out of 100 is used to represent relative search interest over the given time period and geography.

EpiNorth3 data were used to compare cases from phases 2–7, 2020 to historic cases (2015–2019). A univariate case–case analysis was performed using exposure data, with cases reporting foreign travel excluded from analyses of other exposure categories. Comparisons were made between symptom presentation for historic and 2020 cases. Time periods between onset date and specimen date and specimen date and referral date, and the duration of illness were determined, and a Mann-Whitney U test performed. Data from 2019 and 2020 were used to look at differences in laboratory diagnostic testing methods tests used, to account for the increasing use of molecular based techniques in recent years.

All variables were plotted in a time series together with the weekly 5-year average and superimposed COVID-19 outbreak phases, unless otherwise specified. Statistical analyses were performed using Stata software V.14.2.

Patient and public involvement
This study used routinely collected surveillance data. Patients were not involved in the development of the research question and outcome measures, the design of the study, the recruitment and conduct of the study.

RESULTS
Changing trends of GI infections during the different ‘phases’ of the COVID-19 outbreak
During the first 7 months of 2020, 1544 suspected and laboratory-confirmed GI outbreaks were reported in England, representing a 52% decrease on the 5-year average for the period (3208 (95% CI 2938 to 3478)). During the ‘pre-outbreak’ (phase 1; weeks 1–4), notified GI outbreaks were comparable to historic figures (figure 1 and online supplemental table 1). From week 7 (‘early outbreak’, phase 2) there was a 22% decrease in GI outbreaks (510 outbreaks vs 5-year average: 651 (95% CI 605 to 697)), with this decreasing trend continuing to an 87% reduction in GI outbreaks during ‘late lockdown’ (phase 5; weeks 19–22; 5-year average: 46 vs 350 outbreaks (95% CI 294 to 406)). Reported outbreaks remained substantially lower than historically observed for the duration of the COVID-19 response period.

Historically, around 95% of suspected or confirmed GI outbreaks reported in England are attributed to viral GI pathogens (94% in 2020; online supplemental table 1) primarily occurring in health and social care settings. During the COVID-19 response period (phases 2–7), there was a 62% reduction in the number of reported suspected and confirmed viral outbreaks (862 vs 2239), with significant reductions in parasitic outbreaks (2 vs 32 (95% CI 21 to 44); 94% decrease) and bacterial outbreaks (47% decrease; 51 vs 97 outbreaks (95% CI 77 to 115)). Significant decreases in laboratory-confirmed GI cases also occurred, with 27 859 cases reported between phases 2 and 7 compared with a 5-year average of 42 495 (95% CI 40 068 to 44 922; 34% decrease; figure 1 and online supplemental table 1). Decreased reports were apparent from week 10 (‘pre-lockdown’; phase 3; 11% decrease), with a low of 2859 cases reported between weeks 13 and 18 (‘early lockdown’; phase 4) representing a 66% decrease (5-year average: 8345; (95% CI 7602 to 9088)). Laboratory-confirmed cases began to increase from week 16 onwards, mirroring the historic seasonal trend for reported GI pathogen activity despite numbers remaining significantly lower than average; during the historic peak for laboratory reporting, which occurred during lockdown easing, 4617 cases were reported compared with the 5-year average of 7879 ((95% CI 7539 to 8219); 41% decrease).

While the total number of laboratory-confirmed cases was reduced, causative organisms were differently impacted when compared with the 5-year average. Norovirus reports were most reduced (5.6% of all laboratory-confirmed reports vs 9.0%), with reductions also observed for Salmonella spp (7.9% vs 9.5%) and Cryptosporidium spp (2.8% vs 3.9%). The proportion of laboratory-confirmed cases with Giardia spp (5.4% vs 5.2%), STEC (1.2% vs 1.2%) and Listeria spp (0.2% vs 0.2%) during the outbreak period remained comparable, while the proportion of Campylobacter spp reports were increased (74% vs 68%).

Reported norovirus cases decreased substantially during phases 3 and 4 (weeks 11–14; figure 2A), remaining significantly below the 5-year average to week 31. A similar trend was observed for Cryptosporidium spp, which contrasted with historic trends where a spike in activity was observed between weeks 14 and 18 (phase 4; 89 vs 477 cases (95% CI 323 to 631)) and Giardia (figure 2B,C). The bacterial pathogens Shigella spp, Salmonella spp and Campylobacter spp, all showed significant decreases during phase 3, remained low during phase 4 but then began to increase during phase 5, following the 5-year average but with a significantly reduced number of cases reported.

Geographical differences in laboratory-confirmed diagnoses were observed across England’s nine regional areas (figure 4 and online supplemental figure 2). Prior to the COVID-19 outbreak, GI laboratory-confirmed cases in all regions were above the regional 5-year average with the highest difference in the North East, London and South East regions. By the ‘pre-lockdown phase’ (phase 3), laboratory diagnoses had decreased below the 5-year average in all but the North East, and by lockdown (phases 4 and 5), all regions were below historical figures. Lockdown easing (phases 6 and 7) resulted in small increases in GI diagnoses across all regions, with the North West (NW) showing the smallest decrease in GI pathogens over the lockdown and easing periods, compared with historical figures. There was a significant correlation between upper tier local authorities showing smaller decreases
in GI laboratory reports during the COVID-19 outbreak period (phases 2–7) and those with highest COVID-19 rates up to week 31 (Pearson’s correlation 0.18, p=0.03; online supplemental figure 3).

**Contribution of health-seeking behaviour and healthcare provision to changes in reported GI illness during the COVID-19 outbreak**

Observed changes may reflect a real decrease in incidence or may be due to changes to healthcare provision or altered health-seeking behaviour or laboratory testing practices, resulting in reduced surveillance system ascertainment. ED attendances for gastroenteritis (as a proportion of attendances with a diagnostic code) decreased substantially in week 11 to a low in week 14, remaining substantially lower than the 2019 comparator up to week 31 (figure 5A and online supplemental figure 4). Gastroenteritis consultations in GP-out of hours services also decreased during the ‘pre-lockdown phase’ (phase 3; weeks 10–12), increasing slightly at around week 26 but again remaining consistently low across the period.
A similar trend was also observed for gastroenteritis consultations to GP-in-hours services (figure 5C). Finally, calls to the NHS 111 helpline for diarrhoea and vomiting combined began to decrease from week 8 to a low at around week 12 (figure 5D). Calls showed a gradual increase over time, remaining substantially lower than calls observed in 2019. There were no differences in the observed trends for diarrhoea or vomiting as separate symptoms (online supplemental figure 5).

Decreases in GP-in-hours consultations were predominantly observed in younger age groups with substantially decreased age-specific rates seen for children under 14 years during the ‘pre-lockdown phase’ (phase 3), and rates remaining low to week 31 (online supplemental figure 6). More modest decreases were observed at week 11 for adults and the elderly, with consultation rates remaining stable during lockdown and lockdown easing. Trends for UKHSA regions (rate per 100 000 population) were comparable, with decreases for all regions in the ‘pre-lockdown phase’ and slight increases during lockdown easing (online supplemental figure 7).

Enhanced specimen and exposure information was obtained from EpiNorth3 for laboratory-confirmed North East cases. During the outbreak period, 228 cases were reported compared with 2225 between 2015 and 2019 (74% and 80% with a recorded onset date, respectively). There was no difference in the time between onset date and specimen date for cases reported in phase 2–phase 7 2020, compared with historic cases (7 days IQR: 3–14 vs 7 days (4–12 days); Wilcoxon rank-sum p=0.600), with onset to specimen time comparable across the seven phases of the COVID-19 outbreak. The time between specimen date and referral date and proportion of samples processed by culture (76.5% vs 75.7%) and molecular techniques (17.2% vs 15.5%) were also comparable. However, the proportion of specimens processed by light microscopy (protozoa) decreased (2.3% vs 7.6%). The proportion of specimens submitted by GPs was 60.2% compared with 61.3% historically, while a small decrease was observed in specimens from EDs (5.1% vs 8.4%) and a small increase from hospital inpatients (29.6% vs 25.2%).

Analysing EpiNorth3 data it was possible to explore illness duration and symptoms for cases with a completed surveillance questionnaire (n=179 (2020); n=1870 (2015–2019)). The proportion of current cases and historic cases reporting diarrhoea (40% vs 38%) and vomiting (39% vs 42%) were comparable, with an increase in cases reporting bloody diarrhoea in 2020 (24% vs 16%). When comparing 2020 to historic cases, there was no difference in the duration of illness (7.5 days IQR: 5–12 vs 8 days (6–12 days); Wilcoxon rank-sum p=0.980), however, as most cases are symptomatic when interviews are

Figure 4 Laboratory-confirmed gastrointestinal cases* by UK Health Security Agency region and COVID-19 outbreak phase, percentage change compared with the 5-year average for the region. *Organisms: Campylobacter spp, STEC O157, STEC non-O157, Listeria spp, non-typhoidal Salmonella spp, typhoidal Salmonella, Shigella spp, norovirus, Cryptosporidium spp and Giardia spp.
performed (~26% of current and historic cases), completion of this field is low.

**Contribution of population behavioural change to impacts of COVID-19 on GI illness**

Using EpiNorth3 data it was possible to look at changes in exposures for cases of GI illness reported in North East England during the COVID-19 outbreak period and historically (phase 2–7; 2020: 79% cases reported exposure; n=230 vs. historic cases: reported between 2015 and 2019: 84% cases reported exposure; n=2250; online supplemental table 2). The odds of cases with a GI diagnosis reporting foreign travel were significantly reduced in 2020 (OR: 0.37 (95% CI 0.23 to 0.57); p≤0.001), and there were also significant decreases in the odds of cases reporting exposures to UK visitor attractions (OR: 0.23 (95% CI 0.05 to 0.70); p=0.006) and recreational water exposure in the UK, which includes swimming pools (OR: 0.58 (95% CI 0.34 to 0.94); p=0.024). *Salmonella* and *Cryptosporidium* cases had significantly lower odds of reporting UK food outlet exposures (OR: 0.5 and 0.4, respectively, p=0.03 for both).

Trends in outbreak reporting could also be attributed in part to behavioural change. Significant reductions in health and social care outbreaks caused by all pathogens were observed from the ‘early pandemic phase’ (phase 2) of the COVID-19 response, with 318 care home outbreaks (vs 5-year average: 402 (95% CI 355 to 448)) and 45 healthcare setting outbreaks reported (vs 89 (95% CI 75 to 103); figure 6). In educational settings, the number of outbreaks was comparable to the 5-year average in phase 2, with a decrease observed in phase 3, prior to school closures (53 outbreaks vs 86 (95% CI 70 to 102)). Outbreaks in educational settings remained low following the reopening of schools for specific age groups (~25% of pupils) in week 23 (phase 6; 3 vs 61 outbreaks (95% CI 37 to 84)), with the number of outbreaks increasing during phase 7 (10 vs 51 outbreaks (95% CI 39 to 64)). Outbreaks associated with food outlets also reduced significantly in phase 3, prior to the lockdown period (3 vs 13 (95% CI 9 to 17)) and remained low until phase 7 when pubs and restaurants reopened for dine-in customers (6 vs 13 (95% CI 9 to 17)). Outbreaks classified as ‘other’, which included visitor attractions, were substantially decreased in phase 4, when outbreaks associated with such settings are historically highest (7 vs 51 (95% CI 44 to 57)).

Finally, evidence from Google Trends data showed searches for GI associated phrases such as ‘food poisoning’, ‘gastroenteritis’ and ‘sickness bug’ all decreased dramatically between week 11 and week 13, while trends for ‘handwashing’ and ‘disinfection’ increased substantially between week 8 and week 14, mirroring decreases observed in other surveillance systems (online supplemental figure 8).

**DISCUSSION**

Analysis of routinely collected surveillance data from England’s main laboratory, outbreak and syndromic surveillance systems showed marked changes in GI infection trends during the first 6 months of the COVID-19 response.
outbreak response. Decreases in GI activity were observed across all surveillance indicators as restrictions were implemented in line with increasing COVID-19 activity.15 As COVID-19 cases increased and further restrictions were implemented, health-seeking behaviour changed dramatically in England, with health service attendances decreasing from week 12 across all syndromic indicators.1 18–22 Similar decreases were observed internationally, with speculation that reduced healthcare usage was due to public avoidance, with some evidence that those with milder symptoms were least likely to seek care.3–7 23 However, behavioural surveys conducted during late lockdown and lockdown easing found 70%–80% of participants had continued to seek care, if needed.24 25 Protecting the health system was cited as a reason for healthcare avoidance by 16% of respondents with symptoms, while 10% of individuals reported difficulties in accessing their GP for physical complaints.24 25 In England, a government information campaign was launched from week 17 to encourage the public to continue to seek care, particularly for severe or acute conditions; however, our study shows that GI activity was increasing prior to this. Many syndromic indicators, such as those for non-infectious GI conditions, rapidly returned to baseline levels during lockdown and easing, while GI infections showed more modest increases.18–21

Behavioural studies undertaken during the first wave suggest good adherence to hygiene and social distancing measures by the population,25 26 raising the possibility that widespread infection prevention and hygiene measures implemented during the COVID-19 response have had protective effects to varying degrees dependant on the pathogen and transmission route of GI pathogens. Indeed, evidence suggests that non-pharmaceutical interventions implemented in the response were associated with reductions in influenza activity during the 2019/2020 season.27–29 As with influenza, viral gastroenteritis activity is higher during winter, with outbreaks predominantly associated with person-to-person transmission in health and social care settings; in the 2019/2020 season, this outbreak activity appeared to have been partially curtailed by the COVID-19 response. Enhanced infection control measures were recommended in closed settings during week 8;2 although there was evidence that measures were not being sufficiently implemented until later in the response.30 Reports of outbreaks in food outlet and education settings were also reduced prior to closures announced as part of social distancing measures, and all surveillance indicators remained significantly lower than average despite the partial reopening of schools, restaurants and overseas travel corridors during the lockdown easing phase.2

There was evidence that those pathogens spread predominantly by person-to-person transmission, such as norovirus and Shigella spp, showed greater reductions, while bacterial pathogens, which are more commonly foodborne and therefore less influenced by hygiene and social distancing measures, were least impacted.8 31 It is possible that those individuals with the most severe and prolonged infections, which tend to be bacterial, were more likely to access care, as seen with other diseases.4 6 8 9 However, a true decrease in activity was plausible given the measures implemented. Salmonella activity was likely substantially reduced by government guidance on non-essential foreign travel, in place from week 12. Campylobacter, which is usually foodborne and often associated with incorrect food preparation was less impacted than other GI pathogens, although possible

Figure 6 Number of gastrointestinal outbreaks reported to the UK Health Security Agency by outbreak setting between phases 1 and 7 of the COVID-19 response, with the lower bound* of the 5-year average 95% CI indicated by diamonds.

*Central estimate and upper band of historic data not shown due to small numbers reported in 2020.
Explanations for reductions may include food business closures and improved hygiene limiting the risk of cross-contamination. Cryptosporidiosis has strong seasonality with two peaks, one in late spring associated with *C. parvum* which occurs around lambing season and is often associated with petting farm outbreaks, which were closed as part of the COVID-19 response, and the other, usually larger peak in late summer-early autumn mainly caused by *C. hominis* linked to increased recreational water use and foreign travel. However, in 2020, *C. hominis* cases were virtually absent (Cryptosporidium Reference Unit data). It is likely that the closure of premises such as swimming pools and open farms have played a considerable role in this decline, and their reopening may impact on disease transmission.

Reasons for the changes in the national picture observed for GI infections are likely to be complex and multifactorial, and it is not possible to attribute them to a specific cause. This study was strengthened by the triangulation of data from several surveillance systems; using this approach we could determine that the trends observed were consistent across all indicators. However, while this study has incorporated large national and regional-based surveillance systems, this is not comprehensive and there are other examples of operational GI surveillance systems which have not been included in this study. For example, the UKHSA eFOSS system monitors foodborne and non-foodborne GI outbreaks across England, however, due to a small number of outbreaks reported by the system it was felt that these data were not sufficiently powered to add to the overall findings of the study. There are further limitations to this work; it has not been possible to definitively differentiate the relative contributions of the reduced ascertainment of GI infections versus a true decrease in GI disease burden in this study, which an additional focused analysis could address.

An additional limitation of this study is that negative results are not captured by the SGSS laboratory surveillance system, therefore it was not possible to determine to what degree the changes were due to changes in testing. We were not able to calculate the positivity rate to assess whether only severe cases were being tested, although evidence from the North East suggested that symptomatology was comparable between 2020 cases and historic cases. Guidance was released in week 13 recommending the cessation of routine culture for non-bloody diarrhoea might be considered if laboratories were struggling to deliver the service. However, by then laboratory-confirmed cases were beginning to increase again, while other contemporaneous changes implemented to GI laboratory testing methods, such as the introduction of molecular methods could differentially affect ascertainment of GI pathogens. Furthermore, the smallest decreases in laboratory-confirmed GI infections were observed in the NW and North East regions, which had the highest cumulative rates of COVID-19 over this time period, suggesting either increased laboratory capacity for both the identification of COVID-19 and GI infections, or less effective implementation of COVID-19 control measures resulting in greater spread of GI infections and COVID-19.

This comprehensive review of UKHSA surveillance data demonstrates a marked change in GI infection trends in the context of the COVID-19 epidemic. The change is likely to be multifactorial; changes to health seeking behaviour have undoubtedly played a significant role in the trends observed, and ascertainment through surveillance systems has likely been affected. However, from our observations it appears that there has probably also been a true decrease in the incidence of GI infections most likely associated with control measures for the COVID-19 epidemic, although the extent of the true decrease cannot be fully estimated in light of the multiple influencing factors identified and the variation in the ecology and epidemiology of GI pathogens and transmission routes. The findings of this study show the importance of multiple surveillance systems to allow for the comparative analysis across multiple indicators in order to overcome the negative impact of a pandemic situation on national surveillance systems and allow us to see the effects. Second, because they suggest that if measures such as improved hand hygiene and the effective implementation of infection prevention and control measures in health and social care settings were maintained, then it is possible to see sustained reductions in the burden of GI illness.

This analysis includes only the first 6 months of the COVID-19 outbreak response, and further longitudinal analyses will be performed to explore this further and assess any change as we move into further phases of the pandemic including the relaxation of social distancing measures, further lockdown measures, and the usual winter outbreak period.

**Author affiliations**

1. UK Health Security Agency, London, UK
2. National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, UK
3. National Institute for Health Research Health Protection Research Unit in Emergency Preparedness and Response, King’s College London, London, UK
4. Cryptosporidium Reference Unit, Public Health Wales Microbiology and Health Protection, Singleton Hospital, Swansea, UK
5. National Institute for Health Research Health Protection Research Unit in Behavioural Science and Evaluation, University of Bristol, Bristol, UK

**Acknowledgements** The authors acknowledge the contribution and support from all data providers including: NHS 111 and NHS Digital; GSurveillance, University of Oxford, EMIS/EMIS practices, ClinicRisk, TPP, ResearchOne and participating SystmOne GP practices; Advanced and the participating OOH service providers; participating EDSSS emergency departments, Royal College of Emergency Medicine; North East, North West, Yorkshire, East Midlands, West Midlands, East of England, London, South East Coast, South Central, and South Western NHS Ambulance Trusts and The Association of Ambulance Chief Executives. The authors also wish to thank Petra Manley, Louise Coole, Katri Jalava and Lesley Larkin for comments and Claire Ferraro, Lucy Findlater and Adrian Wensley for technical support.

**Contributors** NKL, SG, IO and GS designed the study. NKL analysed the data, with support from AJE, AD, GS, HH and RM. RMC, AD, SG, JM and RV contributed to the interpretation of the results. NKL, AJE and GS wrote the manuscript with input from all authors. NKL is the guarantor responsible for the overall content.

**Funding** NKL, AJE, RV, HH and GS receive support from the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections. IO receives support from the NIHR HPRU in Behavioural Science and Evaluation. GS, RM and AJE receive support from the NIHR HPRU in Emergency Preparedness and Response. Funding was not applicable to this study. The views...
expressed are those of the author(s) and not necessarily those of the NIHR, UK Health Security Agency or the Department of Health and Social Care.

Map disclaimer The depiction of boundaries on the map(s) in this article does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Nicola K Love http://orcid.org/0000-0003-3750-7158
Alex J Elliot http://orcid.org/0000-0002-6414-3065
Gillian Smith http://orcid.org/0000-0002-4257-0568

REFERENCES